Thomasx Neenan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomasx neenan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomasx Neenan Today - Breaking & Trending Today

NANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIV

NANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIV
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Thomasx Neenan , Gates Foundation , Nanite Inc , Prnewswire Nanite Inc , Melinda Gates Foundation , Receives Funding , Develop Non Viral Delivery Vehicles , Neutralizing Antibodies In Vivo , Melinda Gates , Nanite Chief Business Officer ,

Head-To-Head Analysis: Panbela Therapeutics (NASDAQ:PBLA) versus Mersana Therapeutics (NASDAQ:MRSN)

Panbela Therapeutics (NASDAQ:PBLA – Get Rating) and Mersana Therapeutics (NASDAQ:MRSN – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability. Profitability This table compares Panbela Therapeutics and Mersana Therapeutics’ […] ....

United Kingdom , Michaelt Cullen Jr , Thomasx Neenan , Upifitamab Rilsodotin Upri , Mikhail Papisov , Mersana Therapeutics Inc , Panbela Therapeutics Inc , Panbela Therapeutics , Get Rating , Mersana Therapeutics , Mersana Therapeutic , Given Panbela Therapeutic , Upifitamab Rilsodotin , Panbela Therapeutics Daily , Nasdaq Pbla , Stock Comparison , Stock Analysis ,

AbFero Pharmaceuticals Announces Initiation Of Phase 1 Study For Lead Iron Chelator


AbFero Pharmaceuticals Announces Initiation Of Phase 1 Study For Lead Iron Chelator
Study to Examine Safety of SP-420 in MDS and MF
News provided by
Share this article
Share this article
BOSTON, Feb. 23, 2021 /PRNewswire/  AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the initiation of a Phase 1 study of its lead iron chelator, SP-420, in myelodysplastic (MDS) and myelofibrosis patients (MF) with transfusional iron overload (TIO). 
The opening of this trial in MDS and MF marks another critical step forward on the development path for SP-420, said AbFero CEO Thomas X. Neenan. Following the recently awarded Parkinson s research grants from EUREKA Eurostars and Cure Parkinson s, this trial is an additional building block in our strategy of developing safe chelators for both hematological indications and diseases of aging where iron is implicated. ....

United States , United Kingdom , Ruben Mesa , Elizabeth Bowhay Carnes , Thomasx Neenan , Raymond Bergeron , Mays Cancer Center , Malignant Hematology Program , Ut Health San Antonio , University Of Florida , Abfero Pharmaceuticals Inc , Abfero Ltd , Abfero Pharmaceuticals , Cure Parkinson , Texas Health Science Center San , Adult Non Malignant Hematology Program , San Antonio , Fero Pharmaceuticals , Professor Raymond Bergeron , Media Contact , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ரூபன் மீசா , ரேமஂட் பெர்கெரான் , மேஸ் புற்றுநோய் மையம் , வீரியம் மிக்கது ஹீமாட்டாலஜி ப்ரோக்ர்யாம் ,